Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 3.41
BABY's Cash to Debt is ranked higher than
74% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. BABY: 3.41 )
BABY' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 3.41

Equity to Asset 0.79
BABY's Equity to Asset is ranked higher than
85% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. BABY: 0.79 )
BABY' s 10-Year Equity to Asset Range
Min: -1.79   Max: 0.94
Current: 0.79

-1.79
0.94
Interest Coverage 20.47
BABY's Interest Coverage is ranked higher than
57% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 155.63 vs. BABY: 20.47 )
BABY' s 10-Year Interest Coverage Range
Min: 4.92   Max: 9999.99
Current: 20.47

4.92
9999.99
F-Score: 7
Z-Score: 8.44
M-Score: -2.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.14
BABY's Operating margin (%) is ranked higher than
83% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 6.58 vs. BABY: 12.14 )
BABY' s 10-Year Operating margin (%) Range
Min: -32.53   Max: 15.75
Current: 12.14

-32.53
15.75
Net-margin (%) 8.45
BABY's Net-margin (%) is ranked higher than
83% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. BABY: 8.45 )
BABY' s 10-Year Net-margin (%) Range
Min: -27.59   Max: 14.29
Current: 8.45

-27.59
14.29
ROE (%) 9.64
BABY's ROE (%) is ranked higher than
80% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 5.84 vs. BABY: 9.64 )
BABY' s 10-Year ROE (%) Range
Min: -18.17   Max: 10.21
Current: 9.64

-18.17
10.21
ROA (%) 7.02
BABY's ROA (%) is ranked higher than
83% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. BABY: 7.02 )
BABY' s 10-Year ROA (%) Range
Min: -11.99   Max: 9
Current: 7.02

-11.99
9
ROC (Joel Greenblatt) (%) 43.18
BABY's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 12.42 vs. BABY: 43.18 )
BABY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -130.1   Max: 72.5
Current: 43.18

-130.1
72.5
Revenue Growth (%) 14.30
BABY's Revenue Growth (%) is ranked higher than
90% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. BABY: 14.30 )
BABY' s 10-Year Revenue Growth (%) Range
Min: -61.8   Max: 38.3
Current: 14.3

-61.8
38.3
EBITDA Growth (%) 17.70
BABY's EBITDA Growth (%) is ranked higher than
88% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: -1.20 vs. BABY: 17.70 )
BABY' s 10-Year EBITDA Growth (%) Range
Min: -100   Max: 165
Current: 17.7

-100
165
EPS Growth (%) 21.80
BABY's EPS Growth (%) is ranked higher than
87% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. BABY: 21.80 )
BABY' s 10-Year EPS Growth (%) Range
Min: -52.8   Max: 26
Current: 21.8

-52.8
26
» BABY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BABY Guru Trades in Q3 2013

David Nierenberg 115,603 sh (New)
Steven Cohen 11,179 sh (New)
Jim Simons 16,274 sh (New)
Diamond Hill Capital 1,006,780 sh (+1413.27%)
Paul Tudor Jones 26,000 sh (-4.06%)
» More
Q4 2013

BABY Guru Trades in Q4 2013

Joel Greenblatt 59,506 sh (New)
Jim Simons 172,274 sh (+958.58%)
Steven Cohen 14,137 sh (+26.46%)
David Nierenberg Sold Out
Diamond Hill Capital 973,300 sh (-3.33%)
Paul Tudor Jones 18,099 sh (-30.39%)
» More
Q1 2014

BABY Guru Trades in Q1 2014

Chuck Royce 2,100 sh (New)
Joel Greenblatt 596,487 sh (+902.4%)
Paul Tudor Jones 26,776 sh (+47.94%)
Steven Cohen Sold Out
Diamond Hill Capital 968,350 sh (-0.51%)
Jim Simons 167,945 sh (-2.51%)
» More
Q2 2014

BABY Guru Trades in Q2 2014

Jim Simons 405,145 sh (+141.24%)
Diamond Hill Capital 969,630 sh (+0.13%)
Chuck Royce Sold Out
Joel Greenblatt 595,883 sh (-0.1%)
Paul Tudor Jones 24,823 sh (-7.29%)
» More
» Details

Insider Trades

Latest Guru Trades with BABY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-03-31 Add 902.4%0.21%$22.02 - $27.02 $ 31.2124%596487
Joel Greenblatt 2013-12-31 New Buy0.03%$13.61 - $23.03 $ 31.2161%59506
Ken Fisher 2011-12-31 Sold Out 0.02%$7.43 - $9.78 $ 31.21265%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Natus Medical Inc

Diamond Hill Capital Comments on Natus Medical Inc - Oct 17, 2014

Shares of medical device manufacturer Natus Medical, Inc. (BABY) increased after reporting strong quarterly earnings and raising its full-year 2014 earnings guidance. While the company has shown improvement in margins for some time, this was the best quarter of organic revenue growth for Natus in years.

From Diamond Hill Capital (Trades, Portfolio)'s Small Cap Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Natus Medical Inc - Jun 26, 2014

Shares of infant medical device manufacturer Natus Medical, Inc. (BABY) rose as the company reported strong quarterly earnings, continued margin improvement, and a promising outlook for the year.



From Diamond Hill Capital's Small Cap Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Natus Medical Inc

Diamond Hill Capital Comments on Natus Medical Inc
Shares of medical device manufacturer Natus Medical, Inc. (BABY) increased after reporting strong quarterly earnings and raising its full-year 2014 earnings guidance. While the company has shown improvement in margins for some time, this was the best quarter of organic revenue growth for Natus in years. Read more...
Diamond Hill Capital Comments on Natus Medical Inc
Shares of infant medical device manufacturer Natus Medical, Inc. (BABY) rose as the company reported strong quarterly earnings, continued margin improvement, and a promising outlook for the year. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 34.00
BABY's P/E(ttm) is ranked higher than
79% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 51.90 vs. BABY: 34.00 )
BABY' s 10-Year P/E(ttm) Range
Min: 11.47   Max: 723.45
Current: 34

11.47
723.45
P/B 3.04
BABY's P/B is ranked higher than
71% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. BABY: 3.04 )
BABY' s 10-Year P/B Range
Min: 0.79   Max: 5.69
Current: 3.04

0.79
5.69
P/S 2.85
BABY's P/S is ranked higher than
70% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. BABY: 2.85 )
BABY' s 10-Year P/S Range
Min: 0.95   Max: 8.5
Current: 2.85

0.95
8.5
PFCF 20.81
BABY's PFCF is ranked higher than
90% of the 416 Companies
in the Global Medical Devices industry.

( Industry Median: 623.33 vs. BABY: 20.81 )
BABY' s 10-Year PFCF Range
Min: 12.65   Max: 556
Current: 20.81

12.65
556
EV-to-EBIT 22.77
BABY's EV-to-EBIT is ranked higher than
79% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 35.69 vs. BABY: 22.77 )
BABY' s 10-Year EV-to-EBIT Range
Min: 5.7   Max: 409.7
Current: 22.77

5.7
409.7
Shiller P/E 84.29
BABY's Shiller P/E is ranked higher than
82% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. BABY: 84.29 )
BABY' s 10-Year Shiller P/E Range
Min: 19.55   Max: 2156
Current: 84.29

19.55
2156
Current Ratio 2.70
BABY's Current Ratio is ranked higher than
71% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. BABY: 2.70 )
BABY' s 10-Year Current Ratio Range
Min: 1.3   Max: 16.01
Current: 2.7

1.3
16.01
Quick Ratio 2.20
BABY's Quick Ratio is ranked higher than
74% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. BABY: 2.20 )
BABY' s 10-Year Quick Ratio Range
Min: 0.91   Max: 15.09
Current: 2.2

0.91
15.09

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 23.83
BABY's Price/Net Current Asset Value is ranked higher than
77% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. BABY: 23.83 )
BABY' s 10-Year Price/Net Current Asset Value Range
Min: 1.22   Max: 1418
Current: 23.83

1.22
1418
Price/Tangible Book 7.67
BABY's Price/Tangible Book is ranked higher than
62% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. BABY: 7.67 )
BABY' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 64.5
Current: 7.67

1.02
64.5
Price/DCF (Projected) 1.96
BABY's Price/DCF (Projected) is ranked higher than
86% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 28.89 vs. BABY: 1.96 )
BABY' s 10-Year Price/DCF (Projected) Range
Min: 0.79   Max: 5.92
Current: 1.96

0.79
5.92
Price/Median PS Value 1.19
BABY's Price/Median PS Value is ranked higher than
68% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. BABY: 1.19 )
BABY' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 3.03
Current: 1.19

0.13
3.03
Price/Graham Number 3.41
BABY's Price/Graham Number is ranked higher than
77% of the 417 Companies
in the Global Medical Devices industry.

( Industry Median: 6.95 vs. BABY: 3.41 )
BABY' s 10-Year Price/Graham Number Range
Min: 1.21   Max: 33.06
Current: 3.41

1.21
33.06
Earnings Yield (Greenblatt) 4.40
BABY's Earnings Yield (Greenblatt) is ranked higher than
68% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. BABY: 4.40 )
BABY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 17.5
Current: 4.4

0.2
17.5
Forward Rate of Return (Yacktman) 1.53
BABY's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.54 vs. BABY: 1.53 )
BABY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -104   Max: 74.3
Current: 1.53

-104
74.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:NM4.Germany
Natus Medical Incorporated, a Delaware corporation was incorporated in May 1987. The Company is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The Company's product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn's environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The company's products are categorized into: Neurology and Newborn Care and Other. Neurology includes products for diagnostic electroencephalography (EEG), electromyography (EMG), diagnostic sleep analysis or polysomnography (PSG), intraoperative monitoring (IOM), and transcranial doppler ultrasound technology. Newborn Care and other includes products for newborn care including hearing screening, brain injury, thermoregulation, jaundice management, and various disposable products, as well as products for diagnostic hearing assessment for children through adult populations, and products to diagnose and assist in treating balance and mobility disorders. It purchases materials and components from qualified suppliers that are subject to its quality specifications and inspections. It faces competition from other companies in all of its product lines. The Company's competitors range from small privately-held companies to multinational corporations and their product offerings vary in scope and breadth. The Company is subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements.
» More Articles for BABY

Headlines

Articles On GuruFocus.com
Diamond Hill Capital Comments on Natus Medical Inc Oct 17 2014 
Diamond Hill Small Cap Fund Third Quarter 2014 Commentary Oct 17 2014 
Diamond Hill Capital Comments on Natus Medical Inc Jun 26 2014 
Diamond Hill Small Cap Fund Commentary – First Quarter 2014 Jun 25 2014 
Weekly CEO Sells Highlight: OCZ Technology Group Inc, Workday Inc, Gilead Sciences Inc, Natus Medica Dec 09 2013 
Natus Medical Inc. Reports Operating Results (10-Q) Nov 05 2010 
David Nierenberg’s Top Holdings: MOVE, ESIO, BABY, RSYS, HPY, SPN Aug 27 2010 
Natus Medical Inc. (BABY) VP Finance and CFO Steven J Murphy sells 1,814 Shares Aug 19 2010 
Natus Medical Inc. (BABY) President and CEO James B Hawkins sells 6,796 Shares Aug 19 2010 
Natus Medical Inc. Reports Operating Results (10-Q) Aug 06 2010 

More From Other Websites
Market Thorns, Roses, and All Time Highs... Oct 16 2014
Natus Medical Announces First of Kind Vista Ultrasound System Oct 16 2014
Natus Medical Announces First of Kind Vista Ultrasound System Oct 16 2014
Natus Medical to Hold 2014 Third Quarter Financial Results Conference Call on October 22nd Oct 08 2014
NATUS MEDICAL INC Financials Aug 15 2014
Sirona's EPS Growth Accelerates On Instrument Sales Aug 08 2014
NATUS MEDICAL INC Files SEC form 10-Q, Quarterly Report Aug 08 2014
NATUS MEDICAL INC Files SEC form 8-K, Change in Directors or Principal Officers Aug 01 2014
Natus Medical (BABY) Hits New Lifetime High Jul 28 2014
Natus Medical Jul 23 2014
Natus Medical Inc Earnings Call scheduled for 11:00 am ET today Jul 23 2014
NATUS MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 23 2014
Stocks To Watch: Natus Medical, Gilead... Jul 23 2014
Natus Medical Announces Second Quarter 2014 Financial Results Jul 23 2014
Q2 2014 Natus Medical Incorporated Earnings Release - Before Market Open Jul 23 2014
NATUS MEDICAL INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 12 2014
NATUS MEDICAL INC Files SEC form 8-K, Other Events Jun 09 2014
Natus Medical launches Echo-Screen III Jun 04 2014
Omnicell Retains Balanced View May 29 2014
Cepheid: Updated Research Report May 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK